


NSQAP PT Program Information Collection

Form Approved
 OMB No. 0920-xxxx
 Exp. Date xx/xx/20xx




CFDNA Entry
 CFDNA Review/Submit
 SMA Entry
 SMA Review/Submit
 TREC Entry
 TREC Review/Submit

Welcome to the NSQAP Participant Portal


Newborn Screening identifies conditions that can affect a child's long-term health or survival. CDC's Newborn Screening and Molecular Biology Branch manages the Newborn Screening Quality Assurance Program (NSQAP) to enhance and maintain the quality and accuracy of newborn screening results. The program provides training, consultation, guidelines, and dried blood spot proficiency testing and quality control materials to state public health laboratories and other laboratories responsible for newborn screening in the U.S. and many other countries.

A2LA Accredited PT Provider




CDC's Newborn Screening and Molecular Biology Branch (NSMBB) has been granted ISO/IEC 17043 accreditation by the American Association for Laboratory Accreditation (A2LA). Please consult A2LA Certification #4190-01 for a list of accredited NSMBB proficiency testing programs.

Request Participation (New Participants Only)



If you are interested in participating in this program, complete the Participant Request Form. Products and shipping are free for participating laboratories. Laboratories are responsible for the cost of required documentation, import fees, taxes, and other costs. Participants must report data for each product requested.

NSQAP Public Reports



If you would like to access any previous quarterly and annually public reports, click here.

Calendar: Key Dates and Events

[Click to view Calendar >](#)

Feedback

[Please click here to submit any Feedback >](#)

Contact Us

[Please click here for additional questions >](#)

About NSQAP Self-Service Portal
 This program is cosponsored by the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL).

Copyright © 2021. All rights reserved.

Information
 No Fear Act
 FOIA
 Accessibility
 Privacy
 Disclaimer

Questions?
 Contact Us

CDC estimates the average public reporting burden for this collection of information as 45 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB Control Number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0920-xxxx).

Step 1 – Select PT Program Setup (select PT program/grouping of analytes)

Home > Program List - Select Analyte, Method(s) and Cutoff(s)

Program List - Select Analyte, Method(s) and Cutoff(s)

Program Name	Created On
Acylcarnitines (ACPT)	1/8/2020 10:58 AM
Acylcarnitines (ACPT)	5/14/2020 5:26 PM
Amino Acids and SUAC (AAPT)	1/8/2020 10:58 AM
Amino Acids and SUAC (AAPT)	5/14/2020 5:26 PM
Biotinidase (BIOT)	1/8/2020 10:58 AM
Biotinidase (BIOT)	5/14/2020 5:26 PM
Galactose-1-phosphate Uridyltransferase (GALTPT)	1/8/2020 10:58 AM
Galactose-1-phosphate Uridyltransferase (GALTPT)	5/14/2020 5:26 PM
Glucose-6-phosphate Dehydrogenase (G6PDPT)	1/8/2020 10:58 AM
Glucose-6-phosphate Dehydrogenase (G6PDPT)	5/14/2020 5:26 PM

Step 2 – Selecting analytes to report, analytical method(s) and cutoffs

Home > Setup - Analyte(s), Method(s) and Cutoff(s)

Setup - Analyte(s), Method(s) and Cutoff(s)

Acylcarnitines (ACPT)

Select the analyte(s) you want to report, method(s), and give the cutoff for each analyte. Report ACPT data to two decimal places. e.g. (X.XX)

Select All Analytes

Set All Methods below

Analyte	Method	Cutoff (µmol/L blood)
<input checked="" type="checkbox"/> Low Free Carnitine (C0L1)	Derivatized - MS/MS non-kit	30.00
<input checked="" type="checkbox"/> Low Acetylcarnitine (C2L1)	Derivatized - MS/MS non-kit	
<input checked="" type="checkbox"/> Propionycarnitine (C3)	Derivatized - MS/MS non-kit	
<input checked="" type="checkbox"/> Malonylcarnitine (C3DC) †		
<input type="checkbox"/> Malonylcarnitine + Hydroxybutyrylcarnitine (C3DC+C4OH) †		
<input checked="" type="checkbox"/> Butyrylcarnitine (C4)	Derivatized - MS/MS non-kit	
<input type="checkbox"/> Hydroxybutyrylcarnitine (C4OH) †		
<input checked="" type="checkbox"/> Isovalerylcarnitine (C5)	Derivatized - MS/MS non-kit	
<input checked="" type="checkbox"/> Tropyrcarnitine (C5:1)	Derivatized - MS/MS non-kit	

Step 3 – Select specimen for data entry

Home > Specimen List

Specimen List

View Summary

Specimen

Specimen Number	Program Name	Specimen Status	Modified On	Last Edited By
20202006001	ACPT	Set	8/3/2020 12:08 PM	
20202006002	ACPT	Set	8/3/2020 12:08 PM	
20202006003	ACPT	Set	8/3/2020 12:08 PM	
20202006004	ACPT	Set	8/3/2020 12:08 PM	
20202006005	ACPT	Set	8/3/2020 12:08 PM	

Step 4 - Analytic result and clinical assessment data entry.

Home > Data Entry

Data Entry

Acylcarnitines (ACPT)

Low Free Carnitine (C0(L))

Method* Derivatized - MS/MS ClinSpot® Complete K18 RECIPE Cutoff (µmol/L blood) —

Specimen Number 20202006001 Result µmol/L blood C0(L) Presumptive Clinical Assessment*

Low Acetylcarnitine (C2(L))

Method* Derivatized - MS/MS ClinSpot® Complete K18 RECIPE Cutoff (µmol/L blood) —

Specimen Number 20202006001 Result µmol/L blood C2(L) Presumptive Clinical Assessment*

Propionylcarnitine (C3)

Method* Derivatized - MS/MS ClinSpot® Complete K18 RECIPE Cutoff (µmol/L blood) —

Specimen Number 20202006001 Result µmol/L blood C3 Presumptive Clinical Assessment*

Butyrylcarnitine (C4)

Method* Derivatized - MS/MS ClinSpot® Complete K18 RECIPE Cutoff (µmol/L blood) —